Page 3 - Updated July News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Organon s XACIATOtm (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Organon s XACIATOtm (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyJersey cityJuan camilo arjona ferreiraErica montesProduct serviceCenters for diseaseAmerican sexual health associationExchange commissionAmerican collegeHead of research developmentVaginal gelAvailable nationwideTreat bacterial vaginosisFemales agedHispanic black

A Cultural Framework Is Essential in Patient Care

Recognizing that culture is a multifaceted concept can lead to more careful and thoughtful use of the term.

United statesRethea boerIntj qual health careNational academies pressQual manag health careAnnu rev public healthEthnic disparities in health careInstitute of medicine committee on understandingJ health behavHealth managementTaylor communicationsCultural competence considerations for healthNational healthcare qualityCounsel us commission on civil rightsAgency for healthcare researchHealthcare quality

National Vaccine Injury Compensation Program Aims to Address Vaccine Hesitancy

The proposed Vaccine Injury Compensation Modernization Act is intended to bring valuable updates to the 36-year-old legislation.

United statesUniversity of kentuckyJosephl finkAlexandru davidLloyd smuckerLloyd doggettBethel universityUs courtNational childhood vaccine injuryKentucky pharmacists association professor of leadershipCenters for disease controlNational vaccine injusty compensation programNational vaccine injury programVaccine injury compensation program dataCentre college in danvilleUniversity of kentucky college pharmacy

Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH

ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.

United statesSan diegoSamsung bioepisS samsung bioepiEuropean unionEuropean medicines agencyAlexion pharmaceuticalsAmerican society of hematology annual meeting expositionAmerican society of hematologyBiosimilars initiativeAnnual meetingDesign cellsHematology annual meetingAmerican journalReviewed aprilEuropean medicines

Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs

Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.

United statesRimegepant nurtecHolmbergm zavzpretEli lillyNational institute of neurological disordersNational institute of healthNational instituteNeurological disordersUpdated july